Actively Recruiting
Study of SPC1001 Triple Combination Therapy for Adults With Essential Hypertension Phase 2b, Randomized, Double-Blind, Parallel-Group Trial
Led by Shin Poong Pharmaceutical Co. Ltd. · Updated on 2025-02-14
252
Participants Needed
1
Research Sites
11 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of SPC1001, a fixed-dose triple combination therapy containing candesartan, amlodipine, and indapamide, in adults with essential hypertension. This phase 2b, multicenter, randomized, double-blind trial aims to compare SPC1001 to dual-component therapies of each ingredient over an 8-week period. The study also seeks to understand the contribution of each component at low doses. Participants will be randomly assigned to receive one of several low-dose combination therapies, including SPC1001 and three other comparator treatments. Before randomization, participants will complete a 2-week run-in period taking a placebo alongside lifestyle modification. The investigational drugs will then be administered for 8 weeks to evaluate their effects. During the study, participants will have blood pressure measured regularly, including a primary assessment of mean sitting systolic blood pressure changes from baseline to week 8. Screening assessments will occur within 4 weeks before randomization to confirm eligibility. The study monitors safety and efficacy throughout the treatment period, with follow-up visits to track participant progress and outcomes.
CONDITIONS
Brief Title
Efficacy and Safety of SPC1001 in Patients With Essential Hypertension
Research Team
Y
YeongJin Jeong, Master
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here